Protara Therapeutics Q3 net loss $13.3M; cash runway into mid-2027; key trial data readouts on track

Protara Therapeutics, Inc.

2025-Q3 EPS reported -$0.96 vs consensus -$0.39 ▼ miss (-145.1%)

Net loss of $13.3M ($0.31 per share) vs $11.2M ($0.50 per share) in Q3 2024.
Cash, equivalents and investments $133.6M as of Sept 30, expected to fund operations into mid-2027.
R&D expenses $9.6M, up $1.5M YoY driven by THRIVE-3 startup costs.
ADVANCED-2 interim data from ~25 BCG-Unresponsive NMIBC patients expected 1Q 2026.
STARBORN-1 interim update in pediatric LMs expected 4Q 2025; THRIVE-3 first patient dosing by year-end 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.